Anton Safonov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anton Safonov has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Pedram Razavi
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
16 shared publications - Sarat Chandarlapaty
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
12 shared publications - Ahmet Zehir
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
7 shared publications - Angela Rose Brannon
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
7 shared publications - Carol L. Brown
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications - Chaitanya Bandlamudi
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY
7 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer
Purpose: Recent evidence suggests cyclin E1 (CCNE1) amplification as a potential novel therapeutic target. The clinical significance of CCNE1 amplification in breast cancer remains poorly defined. This study explores the clinicogenomic characteristics of CCNE1-amplified breast cancer. Experimental Design: We analyzed genomic and clinical data from patients included in the MSK Breast Translational database who underwent targeted sequencing between January 2014 and October 2025. Allele-specific copy number, including CCNE1 amplification, was assessed by FACETS. Results: Out of 6,318 breast cancers, 251 (4.0%) had CCNE1 amplification. The prevalence of CCNE1 amplification was lower in HR+/HER2- (2.1%) compared to HER2+ (6.7%) and triple-negative breast cancers (8.7%, P<2.2x10-16). CCNE1 amplification was associated with aggressive clinicopathological features across all receptor subtypes. HR+/HER2- tumors harboring CCNE1 amplification had higher tumor grade (77.1% vs 57.1%, P=8.3x10-04), lack of progesterone receptor expression (27.0% vs 15.2%, P=8.8x10-03) and a higher prevalence of estrogen-receptor low expression (ER ≤10%, 25.4% vs 6.5%, P=8.4x10-07). CCNE1-amplified breast cancers were associated with TP53 alterations, high fraction of genome altered, and whole genome doubling events, reflecting marked chromosomal instability. CCNE1 amplification was associated with significantly shorter PFS on first-line THP in HER2+ subtype (8.4 vs 18.0 months, HR 2.33, 95%CI 1.31–4.12, P=3.8×10⁻³), and non-significant trends toward shorter PFS in HR+/HER2− (HR 1.49, 95%CI 0.86–2.58, P=0.16) and triple-negative cancers (HR 1.43, 95%CI 0.95–2.15, P=0.084). Conclusions:CCNE1 amplification defines a subset of breast cancer characterized by high genomic instability and poor clinical outcomes, supporting its role as a potential biomarker for novel therapeutic strategies in this clinical context.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Open AccessCCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer
Purpose: Recent evidence suggests cyclin E1 (CCNE1) amplification as a potential novel therapeutic target. The clinical significance of CCNE1 amplification in breast cancer remains poorly defined. This study explores the clinicogenomic characteristics of CCNE1-amplified breast cancer. Experimental Design: We analyzed genomic and clinical data from patients included in the MSK Breast Translational database who underwent targeted sequencing between January 2014 and October 2025. Allele-specific copy number, including CCNE1 amplification, was assessed by FACETS. Results: Out of 6,318 breast cancers, 251 (4.0%) had CCNE1 amplification. The prevalence of CCNE1 amplification was lower in HR+/HER2- (2.1%) compared to HER2+ (6.7%) and triple-negative breast cancers (8.7%, P<2.2x10-16). CCNE1 amplification was associated with aggressive clinicopathological features across all receptor subtypes. HR+/HER2- tumors harboring CCNE1 amplification had higher tumor grade (77.1% vs 57.1%, P=8.3x10-04), lack of progesterone receptor expression (27.0% vs 15.2%, P=8.8x10-03) and a higher prevalence of estrogen-receptor low expression (ER ≤10%, 25.4% vs 6.5%, P=8.4x10-07). CCNE1-amplified breast cancers were associated with TP53 alterations, high fraction of genome altered, and whole genome doubling events, reflecting marked chromosomal instability. CCNE1 amplification was associated with significantly shorter PFS on first-line THP in HER2+ subtype (8.4 vs 18.0 months, HR 2.33, 95%CI 1.31–4.12, P=3.8×10⁻³), and non-significant trends toward shorter PFS in HR+/HER2− (HR 1.49, 95%CI 0.86–2.58, P=0.16) and triple-negative cancers (HR 1.43, 95%CI 0.95–2.15, P=0.084). Conclusions:CCNE1 amplification defines a subset of breast cancer characterized by high genomic instability and poor clinical outcomes, supporting its role as a potential biomarker for novel therapeutic strategies in this clinical context.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Purpose:Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody–drug conjugate approved for HER2-positive and HER2-low metastatic breast cancer (MBC). Whether activating mutations in ERBB2 potentiate the response to T-DXd in MBC is unknown. Experimental Design:Patients who received T-DXd for non–HER2-amplified MBC and had somatic sequencing were eligible. Real-world progression-free survival (rwPFS) was calculated using the Kaplan–Meier method. Uni- and multivariable associations were assessed using Cox proportional hazards models. Activating ERBB2 mutations (per OncoKB) were modeled in breast cell lines and examined for the kinetics of T-DXd internalization and the potency of antitumor effects. Results:A total of 272 patients received T-DXd for HER2-nonamplified MBC. ERBB2 mutations were found in 20 (7.3%) patients and were associated with prolonged median rwPFS on T-DXd [11 vs. 6.2 months for wild-type (WT) ERBB2]. After adjusting for age, treatment line, estrogen receptor status, and HER2 IHC, ERBB2 mutations were independently associated with longer rwPFS [HR, 0.49; 95% confidence interval (CI), 0.25–0.96; P = 0.038]. Nine patients (45%) with ERBB2 mutations had HER2 IHC 0 disease; no difference in rwPFS was observed between HER2 IHC 1 to 2+ and 0 (HR, 1.37; 95% CI, 0.35–5.34; P = 0.7). Expression of common ERBB2 mutants in CAMA-1, T47D, and MCF10A cells led to more rapid T-DXd internalization [1.3× (L755S, P < 0.05 t test) to 1.96× (D769Y, P < 0.001 t test)] and lower IC50 (0.017–0.070 μg/mL vs. 2.86 μg/mL) compared with cells expressing WT HER2. Conclusions:ERBB2 activating mutations are associated with longer T-DXd rwPFS in HER2-nonamplified MBC, even when HER2 IHC was 0. ERBB2-mutant breast cancers are more sensitive to T-DXd, independent of HER2 expression levels.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Purpose:Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody–drug conjugate approved for HER2-positive and HER2-low metastatic breast cancer (MBC). Whether activating mutations in ERBB2 potentiate the response to T-DXd in MBC is unknown. Experimental Design:Patients who received T-DXd for non–HER2-amplified MBC and had somatic sequencing were eligible. Real-world progression-free survival (rwPFS) was calculated using the Kaplan–Meier method. Uni- and multivariable associations were assessed using Cox proportional hazards models. Activating ERBB2 mutations (per OncoKB) were modeled in breast cell lines and examined for the kinetics of T-DXd internalization and the potency of antitumor effects. Results:A total of 272 patients received T-DXd for HER2-nonamplified MBC. ERBB2 mutations were found in 20 (7.3%) patients and were associated with prolonged median rwPFS on T-DXd [11 vs. 6.2 months for wild-type (WT) ERBB2]. After adjusting for age, treatment line, estrogen receptor status, and HER2 IHC, ERBB2 mutations were independently associated with longer rwPFS [HR, 0.49; 95% confidence interval (CI), 0.25–0.96; P = 0.038]. Nine patients (45%) with ERBB2 mutations had HER2 IHC 0 disease; no difference in rwPFS was observed between HER2 IHC 1 to 2+ and 0 (HR, 1.37; 95% CI, 0.35–5.34; P = 0.7). Expression of common ERBB2 mutants in CAMA-1, T47D, and MCF10A cells led to more rapid T-DXd internalization [1.3× (L755S, P < 0.05 t test) to 1.96× (D769Y, P < 0.001 t test)] and lower IC50 (0.017–0.070 μg/mL vs. 2.86 μg/mL) compared with cells expressing WT HER2. Conclusions:ERBB2 activating mutations are associated with longer T-DXd rwPFS in HER2-nonamplified MBC, even when HER2 IHC was 0. ERBB2-mutant breast cancers are more sensitive to T-DXd, independent of HER2 expression levels.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Supplemental Figure 1: T-DXd internalizes more rapidly in T47D cells expressing mutant HER2.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Supplemental Figure 1: T-DXd internalizes more rapidly in T47D cells expressing mutant HER2.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Supplemental Figure 2: T-DXd internalizes more rapidly in MCF10A cells expressing mutant HER2.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Supplemental Figure 2: T-DXd internalizes more rapidly in MCF10A cells expressing mutant HER2.
- 9 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5071-5079
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Purpose: Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody–drug conjugate approved for HER2-positive and HER2-low metastatic breast cancer (MBC). Whether activating mutations in ERBB2 potentiate the response to T-DXd in MBC is unknown. Experimental Design: Patients who received T-DXd for non–HER2-amplified MBC and had somatic sequencing were eligible. Real-world progression-free survival (rwPFS) was calculated using the Kaplan–Meier method. Uni- and multivariable associations were assessed using Cox proportional hazards models. Activating ERBB2 mutations (per OncoKB) were modeled in breast cell lines and examined for the kinetics of T-DXd internalization and the potency of antitumor effects. Results: A total of 272 patients received T-DXd for HER2-nonamplified MBC. ERBB2 mutations were found in 20 (7.3%) patients and were associated with prolonged median rwPFS on T-DXd [11 vs. 6.2 months for wild-type (WT) ERBB2]. After adjusting for age, treatment line, estrogen receptor status, and HER2 IHC, ERBB2 mutations were independently associated with longer rwPFS [HR, 0.49; 95% confidence interval (CI), 0.25–0.96; P = 0.038]. Nine patients (45%) with ERBB2 mutations had HER2 IHC 0 disease; no difference in rwPFS was observed between HER2 IHC 1 to 2+ and 0 (HR, 1.37; 95% CI, 0.35–5.34; P = 0.7). Expression of common ERBB2 mutants in CAMA-1, T47D, and MCF10A cells led to more rapid T-DXd internalization [1.3× (L755S, P < 0.05 t test) to 1.96× (D769Y, P < 0.001 t test)] and lower IC50 (0.017–0.070 μg/mL vs. 2.86 μg/mL) compared with cells expressing WT HER2. Conclusions: ERBB2 activating mutations are associated with longer T-DXd rwPFS in HER2-nonamplified MBC, even when HER2 IHC was 0. ERBB2-mutant breast cancers are more sensitive to T-DXd, independent of HER2 expression levels.
- 9 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5071-5079
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-Nonamplified Metastatic Breast Cancer
Purpose: Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody–drug conjugate approved for HER2-positive and HER2-low metastatic breast cancer (MBC). Whether activating mutations in ERBB2 potentiate the response to T-DXd in MBC is unknown. Experimental Design: Patients who received T-DXd for non–HER2-amplified MBC and had somatic sequencing were eligible. Real-world progression-free survival (rwPFS) was calculated using the Kaplan–Meier method. Uni- and multivariable associations were assessed using Cox proportional hazards models. Activating ERBB2 mutations (per OncoKB) were modeled in breast cell lines and examined for the kinetics of T-DXd internalization and the potency of antitumor effects. Results: A total of 272 patients received T-DXd for HER2-nonamplified MBC. ERBB2 mutations were found in 20 (7.3%) patients and were associated with prolonged median rwPFS on T-DXd [11 vs. 6.2 months for wild-type (WT) ERBB2]. After adjusting for age, treatment line, estrogen receptor status, and HER2 IHC, ERBB2 mutations were independently associated with longer rwPFS [HR, 0.49; 95% confidence interval (CI), 0.25–0.96; P = 0.038]. Nine patients (45%) with ERBB2 mutations had HER2 IHC 0 disease; no difference in rwPFS was observed between HER2 IHC 1 to 2+ and 0 (HR, 1.37; 95% CI, 0.35–5.34; P = 0.7). Expression of common ERBB2 mutants in CAMA-1, T47D, and MCF10A cells led to more rapid T-DXd internalization [1.3× (L755S, P < 0.05 t test) to 1.96× (D769Y, P < 0.001 t test)] and lower IC50 (0.017–0.070 μg/mL vs. 2.86 μg/mL) compared with cells expressing WT HER2. Conclusions: ERBB2 activating mutations are associated with longer T-DXd rwPFS in HER2-nonamplified MBC, even when HER2 IHC was 0. ERBB2-mutant breast cancers are more sensitive to T-DXd, independent of HER2 expression levels.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- Open Access
- 18 October 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-9
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was both safe and effective, with a median time to treatment failure (TTF) of 10.1 months (95%CI, 4.8–16.9). For patients whose disease progressed on a prior CDK4/6i, we demonstrated comparable median TTFs for patients rechallenged with the same CDK4/6i (4.3 months, 95%CI 3.2–5.5) and with a different CDK4/6i (4.7 months, 95%CI 3.7–6.0) when compared to the recent PACE, PALMIRA, and MAINTAIN trials. Exploratory genomic analysis suggested that the presence of mutations known to confer CDK4/6i resistance, such as TP53 mutations, CDK4 amplifications, and RB1 or FAT1 loss of function mutations may be molecular biomarkers predictive of CDK4/6i retrial failure.
- 18 October 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-9
Open AccessPredictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was both safe and effective, with a median time to treatment failure (TTF) of 10.1 months (95%CI, 4.8–16.9). For patients whose disease progressed on a prior CDK4/6i, we demonstrated comparable median TTFs for patients rechallenged with the same CDK4/6i (4.3 months, 95%CI 3.2–5.5) and with a different CDK4/6i (4.7 months, 95%CI 3.7–6.0) when compared to the recent PACE, PALMIRA, and MAINTAIN trials. Exploratory genomic analysis suggested that the presence of mutations known to confer CDK4/6i resistance, such as TP53 mutations, CDK4 amplifications, and RB1 or FAT1 loss of function mutations may be molecular biomarkers predictive of CDK4/6i retrial failure.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Supplementary Figures S1-S5 Supplementary Tables S1-S5
- 6 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (20) , 3478-3489
A Genomics-Driven Artificial Intelligence – Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image. Significance: Genetic alterations linked to strong genotypic–phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.
- 6 August 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (20) , 3478-3489
A Genomics-Driven Artificial Intelligence – Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to histologic whole-slide images using CDH1 biallelic mutations, pathognomonic for invasive lobular carcinoma (ILC) in breast neoplasms, as ground truth. The model accurately predicted CDH1 biallelic mutations (accuracy = 0.95) and diagnosed ILC (accuracy = 0.96). A total of 74% of samples classified by the AI model as having CDH1 biallelic mutations but lacking these alterations displayed alternative CDH1 inactivating mechanisms, including a deleterious CDH1 fusion gene and noncoding CDH1 genetic alterations. Analysis of internal and external validation cohorts demonstrated 0.95 and 0.89 accuracy for ILC diagnosis, respectively. The latent features of the AI model correlated with human-explainable histopathologic features. Taken together, this study reports the construction of an AI algorithm trained using a genetic rather than histologic ground truth that can robustly classify ILCs and uncover CDH1 inactivating mechanisms, providing the basis for orthogonal ground truth utilization for development of diagnostic AI models applied to whole-slide image. Significance: Genetic alterations linked to strong genotypic–phenotypic correlations can be utilized to develop AI systems applied to pathology that facilitate cancer diagnosis and biologic discoveries.
- Open Access
- 2 May 2024
- Published by Springer Nature in Research Square
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was both safe and effective, with a median time to treatment failure (TTF) of 10.1 months (95%CI, 4.8-16.9). For patients whose disease progressed on a prior CDK4/6i, we demonstrated comparable median TTFs for patients rechallenged with the same CDK4/6i (4.3 months, 95%CI 3.2-5.5) and with a different CDK4/6i (4.7 months, 95%CI 3.7-6.0) when compared to the recent PACE, PALMIRA, and MAINTAIN trials. Exploratory genomic analysis suggested that the presence of mutations known to confer CDK4/6i resistance, such as TP53 mutations, CDK4 amplifications, and RB1 or FAT1 loss of function mutations may be molecular biomarkers predictive of CDK4/6i retrial failure.
- 2 May 2024
- Published by Springer Nature in Research Square
Open AccessPredictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retrial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was both safe and effective, with a median time to treatment failure (TTF) of 10.1 months (95%CI, 4.8-16.9). For patients whose disease progressed on a prior CDK4/6i, we demonstrated comparable median TTFs for patients rechallenged with the same CDK4/6i (4.3 months, 95%CI 3.2-5.5) and with a different CDK4/6i (4.7 months, 95%CI 3.7-6.0) when compared to the recent PACE, PALMIRA, and MAINTAIN trials. Exploratory genomic analysis suggested that the presence of mutations known to confer CDK4/6i resistance, such as TP53 mutations, CDK4 amplifications, and RB1 or FAT1 loss of function mutations may be molecular biomarkers predictive of CDK4/6i retrial failure.